Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Early Phase 1
1(33.3%)
Phase 2
1(33.3%)
N/A
1(33.3%)
3Total
Early Phase 1(1)
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07508839Not ApplicableNot Yet Recruiting

Evaluation of the Safety and Efficacy of SALI-10 Probiotic Lozenges

Role: lead

NCT07256743Phase 2Recruiting

Efficacy of SALI-10 Oral Probiotics in Experimental Gingivitis

Role: lead

NCT06819761Early Phase 1Not Yet Recruiting

Determining the Viability a Lozenge Dosage for Probiotics

Role: lead

All 3 trials loaded